Check out this @ACCinTouch publication, "#Pharmacodynamic Effects of Vorapaxar in Patients With and Without #Diabetes Mellitus," featuring thought leadership from Dr. Lisa K Jennings. 🔗https://t.co/qCcgu8BNLb 🔗https://t.co/6IujqWIR1l #cardiology #hemat
RT @HanCardiomd: OPTIMUS-5 : Vorapaxar leads to greater clinical benefit when added to the standard of care in diabetes mellitus patients o…
OPTIMUS-5 : Vorapaxar leads to greater clinical benefit when added to the standard of care in diabetes mellitus patients on DAPT. https://t.co/7XfOoYx1mg @JACCJournals @AnastasiaSMihai @DrMarthaGulati @escardio @purviparwani @DLBHATTMD @EAPCIPresident @SAB
RT @JACCJournals: #ESCCongress study in #JACCBTS finds that #vorapaxar is associated with reduced platelet-mediated thrombogenicity without…
RT @JACCJournals: #ESCCongress study in #JACCBTS finds that #vorapaxar is associated with reduced platelet-mediated thrombogenicity without…
RT @JACCJournals: #ESCCongress study in #JACCBTS finds that #vorapaxar is associated with reduced platelet-mediated thrombogenicity without…
#ESCCongress study in #JACCBTS finds that #vorapaxar is associated with reduced platelet-mediated thrombogenicity without affecting clot kinetics irrespective of diabetes status. But, platelet-mediated thrombogenicity increased after aspirin withdrawal: ht